Feature

What’s Driving the Higher Breast Cancer Death Rate in Black Women?


 

Hope for Improved Outcomes, Higher Survival Rates

Investigators hope the findings of all of this new research lead to better, more targeted treatments and, in turn, improved outcomes.

Dr. Haricharan is optimistic about the improvement of breast cancer outcomes as more is learned about the biology of Black patients and other non-White patients.

There is a growing effort to include more data from minoritized populations in breast cancer research studies, Dr. Haricharan said, and she foresees associated changes to clinical protocols in the future. Her own team is working on creating larger data sets that are more representative of non-White patients to further analyze the differences found in their prior study.

“I think there’s this understanding that, until we have data sets that are more representative, we really are catering to [only one] population in terms of our diagnostic and therapeutic technological advances,” she said.

The American Cancer Society meanwhile, is launching a new initiative in May that aims to collect more health data from Black women to ultimately develop more effective cancer interventions. VOICES of Black Women will focus on collecting and studying health data from Black women through online surveys. The society’s goal is to enroll at least 100,000 Black women in the United States between ages 25 and 55.

Dr. Miller-Kleinhenz called the initiative “an important step to starting to research and answer some of these lingering questions about why there continue to be breast cancer disparities.”

Pages

Recommended Reading

High TIL Levels Linked to Improved Prognosis in Early TNBC Even in Absence of Chemotherapy
MDedge Hematology and Oncology
Novel Treatment Sequence Speeds Up Breast Reconstruction Procedures in Patients With Breast Cancer
MDedge Hematology and Oncology
MRI-Based Strategy Can Limit Neoadjuvant Chemotherapy Duration in HR−/HER2+ BC
MDedge Hematology and Oncology
Breast Cancer Radiation Therapy Raises Risk for Nonkeratinocyte Skin Cancer
MDedge Hematology and Oncology
Antibiotic Exposure During Immunotherapy Increases Disease Burden in HER2− Early BC
MDedge Hematology and Oncology
Adjuvant Chemotherapy May be Omitted in Older Women Aged 80 Years or Older With HR+/HER2- BC
MDedge Hematology and Oncology
Impact of Adjuvant Ovarian Function Suppression on Recurrence Risk in Premenopausal HR+ Breast Cancer
MDedge Hematology and Oncology
Hormone + Radiation Therapy Better Than Either Treatment in Older Men With Early HR+ BC
MDedge Hematology and Oncology
Most Targeted Cancer Drugs Lack Substantial Clinical Benefit
MDedge Hematology and Oncology
Certain Women May Face Higher Risk for Second Breast Cancer
MDedge Hematology and Oncology